According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product ...

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.

Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of ...

Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its stock increase by 4% after the company announced that the FDA had approved ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...

Investing.com -- Amphastar Pharmaceuticals (NASDAQ: AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with chro ...

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.4% in the morning session after the company announced it received U.S. Food and Drug Administration (FDA) approval for ...

Type 2 diabetes in children is not just a “sugar problem”, it’s a complex metabolic disorder with lifelong implications ...

Cane sugar is the latest talk on the health halo street. Is it a healthier alternative to corn syrup or just another sugar ...